[A20-106] Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 04.06.2021

Project no.:
A20-106

Commission:
Commission awarded on 02.12.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer susceptibility gene (BRCA)1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent (NHA)

Result of dossier assessment:

Patients for whom abiraterone or enzalutamide is the best individual choice: hint of minor added benefit.

Patients for whom docetaxel or cabazitaxel is the best individual choice: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021.06.04 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.